Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy.

  title={Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy.},
  author={Andrew T. Canada and Lawrence J. Lesko and Charles I. Haffajee and Bruce W Johnson and G K Asdourian},
  journal={Drug intelligence & clinical pharmacy},
  volume={17 2},
Amiodarone, although widely studied in Europe, is a recent addition to the investigational antiarrhythmics being used in the U.S. Pharmacologically, its primary cardiac effects are to increase coronary artery blood flow, increase the effective refractory period, and produce an atropine-resistant bradycardia. Amiodarone is incompletely (approximately 50 percent) and slowly (peak serum concentration approximately 6 h) absorbed. With chronic administration, it deposits both in adipose tissue and… CONTINUE READING